| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies ...
HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.
https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm
HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.
HC Wainwright & Co. analyst Yi Chen maintains ASLAN Pharma (NASDAQ:ASLN) with a Buy and lowers the price target from $17...
Piper Sandler analyst Edward Tenthoff reiterates ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fr...
